Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394] Awaiting development [GID-TA11808] Expected publication date: TBC . Project information .

The field of cytokine biology has seen significant advancements, particularly concerning Interleukin-5 (IL-5) and its role in eosinophil-related disorders.

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra (benralizumab) - which ...

Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the history of present illness for a case of severe asthma with nasal polyps.

AZN | A complete AZN overview by MarketWatch. View the latest market news and prices, and trading information.

AZN | Complete AstraZeneca PLC stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric ...